PE20181895A1 - Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer - Google Patents

Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer

Info

Publication number
PE20181895A1
PE20181895A1 PE2018001829A PE2018001829A PE20181895A1 PE 20181895 A1 PE20181895 A1 PE 20181895A1 PE 2018001829 A PE2018001829 A PE 2018001829A PE 2018001829 A PE2018001829 A PE 2018001829A PE 20181895 A1 PE20181895 A1 PE 20181895A1
Authority
PE
Peru
Prior art keywords
compounds
cinnolin
amine compounds
cancer
hydro
Prior art date
Application number
PE2018001829A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20181895A1 publication Critical patent/PE20181895A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a compuestos cinnolin-4-amina sustituidas de formula (I) y sus sales farmaceuticamente aceptables; en donde R1 es alquilo (C1-C3); R2 es hidro o alquilo (C1-C3); o R1 y R2 junto al N pueden formar un azetidino, pirrolidino o piperidinilo; y R3 es hidro o metilo. Estos compuestos modulan selectivamente la cinasa de ataxia telangiectasia mutada (ATM cinasa), incluyendo el cancer. Un compuesto seleccionado es: 6-[6-(3-dimetilaminopropoxi)piridin-3-il]-N-metil-4-[[(1S)-1-(oxan-4-il)etil]amino]cinnolin-3-carboxamida. Tambien se refiere a composiciones farmaceuticas que comprenden dichos compuestos y sales de los mismos; intermedios utiles en la fabricacion de dichos compuestos y metodos para tratar una enfermedad mediada por ATM incluyendo el cancer.
PE2018001829A 2016-03-21 2017-03-20 Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer PE20181895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662310883P 2016-03-21 2016-03-21

Publications (1)

Publication Number Publication Date
PE20181895A1 true PE20181895A1 (es) 2018-12-11

Family

ID=58361025

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001829A PE20181895A1 (es) 2016-03-21 2017-03-20 Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer

Country Status (18)

Country Link
US (1) US20190099421A1 (es)
EP (1) EP3433251A1 (es)
JP (1) JP2019512512A (es)
KR (1) KR20180127419A (es)
CN (1) CN108884084A (es)
AR (1) AR107937A1 (es)
AU (1) AU2017237394A1 (es)
BR (1) BR112018068347A2 (es)
CA (1) CA3017035A1 (es)
CO (1) CO2018010951A2 (es)
DO (1) DOP2018000197A (es)
IL (1) IL261648A (es)
MA (1) MA43733A (es)
MX (1) MX2018011283A (es)
PE (1) PE20181895A1 (es)
SG (1) SG11201806982PA (es)
TW (1) TW201808939A (es)
WO (1) WO2017162605A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111344293A (zh) * 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
RU2020133020A (ru) * 2018-03-14 2022-04-14 Мерк Патент Гмбх Соединения и их применения для лечения опухолей у субъекта
CN115636833A (zh) * 2018-09-14 2023-01-24 苏州赞荣医药科技有限公司 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
EP2668162A1 (en) 2011-01-28 2013-12-04 Novartis AG Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
BR112013030095A2 (pt) * 2011-05-23 2019-09-24 Elan Pharm Inc inibidores de atividade de lrrk2 cinase
NO2714752T3 (es) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
CO2018010951A2 (es) 2018-10-22
US20190099421A1 (en) 2019-04-04
JP2019512512A (ja) 2019-05-16
EP3433251A1 (en) 2019-01-30
TW201808939A (zh) 2018-03-16
MX2018011283A (es) 2019-05-27
BR112018068347A2 (pt) 2019-01-15
WO2017162605A1 (en) 2017-09-28
CN108884084A (zh) 2018-11-23
MA43733A (fr) 2018-11-28
KR20180127419A (ko) 2018-11-28
AU2017237394A1 (en) 2018-11-01
DOP2018000197A (es) 2018-10-15
IL261648A (en) 2018-10-31
CA3017035A1 (en) 2017-09-28
SG11201806982PA (en) 2018-09-27
AR107937A1 (es) 2018-06-28

Similar Documents

Publication Publication Date Title
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
PE20211411A1 (es) Compuestos de anillo fusionado
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
PE20181895A1 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
PE20191486A1 (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal